ECOR — electroCore, Inc.

Summary of electroCore Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $9.2 million, up 31% year-over-year.
• Full Year 2025 Revenue: $32 million, a 27% increase from 2024.
• VA System Revenue: $26 million, a 23% year-over-year increase.
• General Wellness Revenue: $5.5 million for the year, a 97% increase, primarily driven by Truvaga sales.
• Net Loss: $14 million or $1.65 per share, compared to a loss of $11.9 million or $1.59 per share in 2024.
• Adjusted EBITDA Loss: $8.7 million, slightly improved from $9 million in 2024.
• Gross Margin: 87%, significantly improved from 5% in 2024.

2. Strategic Updates and Business Highlights

• Leadership transition announced with CEO Dan Goldberger retiring effective April 1, 2026. CFO Joshua Lev appointed as Interim President, and Michael Fox will join as Chief Operating Officer.
• Continued focus on expanding sales within the VA system and growing the general wellness segment with Truvaga.
• Strong clinical foundation for products, including gammaCore and Quell, with multiple studies supporting efficacy in pain management.
• Truvaga gaining traction in direct-to-consumer channels, with significant media recognition and partnerships.

3. Forward Guidance and Outlook

• Anticipated revenue growth of approximately 30% in 2026, primarily driven by the VA system.
• No detailed guidance provided due to leadership transition, but a commitment to revisit formal guidance in the future.
• Plans to introduce Quell Relief in the first half of 2026, expected to contribute incremental revenue.

4. Bad News, Challenges, or Points of Concern

• Increased operating expenses, totaling $40.9 million for 2025, up from $33.6 million in 2024, primarily due to higher sales and marketing costs.
• The company reported a net loss, indicating ongoing challenges in achieving profitability.
• Concerns about the potential impact of leadership changes on strategic execution and momentum.
• Ongoing challenges with insurance reimbursement coverage, particularly with managed care systems, which may hinder broader adoption.

5. Notable Q&A Insights

• The VA channel is expected to grow with the addition of new sales personnel and the expertise of incoming COO Michael Fox.
• Direct-to-consumer strategies for Truvaga will focus on increasing affiliate partnerships and driving traffic to the company’s website.
• The NHS in England remains a key international focus, although regulatory bottlenecks exist.
• The company is optimistic about the potential for Quell Relief, but revenue from this product is not included in the current guidance.
• The management team is committed to maintaining operational efficiency while pursuing growth opportunities in both federal and wellness markets.

Overall, electroCore demonstrated strong revenue growth in 2025, but faces challenges related to profitability and leadership transitions. The company remains focused on strategic growth in the VA system and expanding its wellness product offerings.